Adhesion Barrier Final Guidance Removes Surrogate Endpoint Distinction
This article was originally published in The Gray Sheet
Executive Summary
FDA's final guidance for resorbable adhesion barrier devices used in abdominal and/or pelvic surgery eliminates the definition of adhesion reduction as a surrogate endpoint